WARRINGTON, Pa., March 26, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it has created a lyophilized formulation of its synthetic, peptide-containing KL4 surfactant technology. Lyophilized KL4 surfactant is being developed to support Discovery Labs’ pipeline of surfactant product candidates including Surfaxin(r) (lucinactant as a liquid formulation) and Aerosurf(r) (lucinactant as an aerosolized formulation). Discovery Labs is developing a pipeline of surfactant-based therapies targeted to address several respiratory disorders associated with surfactant deficiency or dysfunction. Lyophilized KL4 surfactant is manufactured as a dry powder formulation that is reconstituted prior to use. Key next steps include planned discussions with global regulatory agencies intended to determine the development pathway leading to the initiation of a late-stage neonatal clinical trial program.
